Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe you are right-- great potential. Eye it carefully each day, particularly yesterday. Currently using E*Trade which doesn't permit off hours trading so typically don't hold ahead of earnings. Already up before could trade this morning so now will wait for a dip.
Good for you, however!
NVTA
Duke Energy +1.4% after easy Q1 earnings beat
May 10, 2018 8:59 AM ET|About: Duke Energy Corporation (DUK)|By: Carl Surran, SA News Editor
Duke Energy (NYSE:DUK) +1.4% premarket as Q1 earnings handily beat expectations and total operating revenue gained 7% Y/Y to $6.1B, helped by higher demand in its electric utilities business.
Q1 income from the Electric Utilities and Infrastructure segment jumped 28% Y/Y to $816M from $635M in the prior-year quarter, helped by a return to normal weather this year compared to the significantly warmer winter weather a year earlier and lower income tax expense.
DUK says its consolidated adjusted effective tax rate for Q1 was 15.7% vs. 32.5% in the year-ago quarter, primarily due to the impacts of the Tax Act.
DUK reaffirms FY 2018 EPS guidance of $4.55-$4.85, in line with $4.72 analyst consensus estimate.
__________________________________________________
https://seekingalpha.com/news/3355255-duke-energy-plus-1_4-percent-easy-q1-earnings-beat?app=1#email_link
DUK
Back in yesterday @ $7.70. Wild day for the stock and I have some concern regarding the supposed accounting issues which were raised late in the day.
ADT
Altimmune to Announce First Quarter 2018 Financial Results on May 16
By GlobeNewswire, May 08, 2018, 08:00:00 AM EDT
GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) --
Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, May 16.
Conference Call Details
Date: Wednesday, May 16
Time: 8:30am Eastern Time
Domestic: 888-394-8218
International: 323-701-0225
Conference ID: 1336227
Webcast: http://public.viavid.com/index.php?id=129546
Replays, Available through May 30th:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 1336227
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
enright@altimmune.com
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com
Source: Altimmune, Inc.
Sold @ $15.15 late in the day after Trump's announcement re: Iran. Can't time the market but there was a big decline following the news and I won't be available tomorrow afternoon to trade so played it safe.
Keep trying to avoid Trump volatility.
NUAN
Good call, believe that $26.00 is past. However, I sold @ $28.29 late in the day after Trump's announcement re: Iran. Can't time the market but there was a big decline following the news and I won't be available tomorrow afternoon to trade so played it safe.
NCR
Continue to be intrigued by Novartis' interest. Increased shares by ~22%:
2018-02-02 SC 13G/A ALT / Altimmune, Inc. 3,084,551 3,775,341 22.40 18.40 -7.54
https://fintel.io/i/novartis-bioventures
ALT
So do I. It is on my Level II platform so I glance at it daily and was in a pretty narrow channel for about a month. Saw it up ~9% and dismissed it as not worth chasing. Surprised it kept gaining momentum all day.
Now over-bought and will be interesting to see if it holds.
Now seeing CYH is up about ~9% today -- same sector.
THC
Out earlier @ .76 selling remaining shares from earlier partial sell. Was unwilling to buy higher.
Chart is great with the PSAR flipping today and PMO the remaining positive signal about to cross-over.
Just got caught off guard by the strength of volume and momo. Will buy back should there be a dip.
ALT
Morgan Stanley: 3 ‘Strong Buy’ Takeover Targets in Tech
Harriet Lefton April 25, 2018 0 Comments
Morgan Stanley has identified tech companies most likely to get acquired in the next 12 months. Takeovers are on the rise thanks to tax cuts, which frees up cash for deals according to the bank. Indeed, acquisition intensity increased to 3.2% in Q1 from 2.5% in the previous quarter. Why does this matter? Well, share prices can soar when a takeover deal is announced- meaning that there is big value in identifying takeover targets correctly.
From the list, we used TipRanks to identify the top stocks with a bullish Street outlook. All three of the stocks below boast a ‘Strong Buy’ analyst consensus rating. The advantage of these three stocks is that they represent compelling investing opportunities- even if a takeover doesn’t materialize.
As for the methodology, “Our model, ALERT (Acquisition Likelihood Estimate Ranking Tool), combines stock characteristics, cohort membership, and data regarding offers to forecast probabilities that stocks receive tender offers in the coming 12 months,” revealed Brian Hayes, the firm’s global head of quantitative research.
So with this in mind, let’s take a closer look now:
2. Nuance Communications (NASDAQ:NUAN)
Nuance- the company that provides the tech for Apple’s Siri, boasts 100% Street support right now. Analysts are projecting, on average, 39% upside potential from current levels. One of these analysts is Oppenheimer’s Shaul Eyal. This top 100 analyst sees big expansion potential for NUAN and explains why here:
The speech market remains relatively under-penetrated, providing significant opportunity to expand market reach. As a stock, NUAN should benefit from the company’s market-leading position and nascent opportunity in speech solutions.
Plus the appointment of a new CEO Mark Benjamin will bring new blood to push NUAN’s long-term strategy. Mark Benjamin is replacing former CEO Paul Ricci.
__________________________________________
https://blog.tipranks.com/morgan-stanley-3-strong-buy-takeover-targets-tech/
NUAN
Yep, seems strong during the last 15 min for the past several days. FWIW, BarChart seems to have nailed recent action on their CheatSheet:
Pivot Point 1st Resistance Point 0.76
High 0.75 High
0.73 14-3 Day Raw Stochastic at 20%
Previous Close 0.72 Previous Close
0.72 Pivot Point
Last 0.70 Last
Pivot Point 1st Support Point 0.67
Low 0.67 Low
__________________________________________
https://www.barchart.com/stocks/quotes/ALT/cheat-sheet
Was ready to buy back shares at .66 but it never got there (also was asking @ .76 and never got there.)
ALT
FDA accepts Sanofi Pasteur's marketing application for expanded use of flu vaccine
Apr. 25, 2018 9:45 AM ET|By: Douglas W. House, SA News Editor
The FDA accepts for review Sanofi Pasteur's (SNY +0.6%) supplemental marketing application seeking approval to use the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) in children ages six months to 35 months. It is is currently approved for use in kids at least 36 months of age.
The agency's action date is January 28, 2019.
Flu vaccine-related tickers: (ALT)(GSK -3.8%)(AZN -0.4%)(BVXV)
_______________________________________________
https://seekingalpha.com/news/3348542-fda-accepts-sanofi-pasteurs-marketing-application-expanded-use-flu-vaccine?app=1&uprof=46#email_link
ALT
Very interesting stock to watch. Still maintain this is being highly manipulated. Even though a low float when I sold shares last week @ $.83 could only get partial fill. However other shares were sold at that price. Moved my target down to .76 for today and sold some there but EDGX provided only a partial sell which was immediately followed by another sale at that price which would have covered all my shares waiting to be sold. Earlier in the day I was the only one asking @ $.76. Trades never make sense here.
Now have a small position at the time the chart seems poised to break out for almost ever indicator:
The only neutral indicator I see is PMO while the rest are all positive.
ALT
Back in @ $15.20. Hard to trade with Trump rumors.
NUAN
See your point. Watched CLDX today which was trading in the low .70s and although it had far greater volume due to their recent miss there was a similar close spread and movement. Although the ALT spread was greater today the effect was much the same with much of the time one MM on bid and one on ask. They would go long periods with the same bid/ask and same # of shares offered but meanwhile trade thousands of shares exceeding those on the Level II. There should be a better system; only MMs made money today unless one was trading a very large number of shares.
Too frustrating -- will try to sell the rest at opening @ .83.
Are you day trading or long?
ALT
I may be over-analyzing. I tend to be conservative so sold about half of shares this morning at .83 (have the rest still at ask). So we'll see -- still think ALT is good in the long run.
ALT.
Yep, but generally down with high volume. Doesn't usually trade out of regular hours. The last 3 days it has become a different animal:
After Hours Time (ET) After Hours Price After Hours Share Volume
17:58:19 $ .743 665
17:57:50 $ .745 50
17:57:50 $ .75 50
17:57:50 $ .75 25
17:08:29 $ .795 400
17:08:29 $ .795 100
17:01:00 $ .793 1
16:50:29 $ .74 445
16:50:28 $ .74 500
16:50:27 $ .74 2,000
16:50:24 $ .739 1,637
16:50:22 $ .739 500
16:50:12 $ .739 150
16:50:12 $ .739 100
16:50:03 $ .739 500
16:49:18 $ .739 400
16:49:18 $ .739 100
16:48:54 $ .739 900
16:48:54 $ .739 100
16:48:40 $ .741 500
16:48:40 $ .75 10
16:46:36 $ .741 4,387
16:46:31 $ .741 100
16:46:31 $ .741 3,000
16:44:51 $ .75 500
16:43:56 $ .75 73
16:43:26 $ .75 400
16:42:48 $ .75 50
16:42:36 $ .75 2
16:41:27 $ .75 1,996
16:39:09 $ .75 1,000
16:39:09 $ .76 1
16:37:59 $ .775 288
16:10:16 $ .79 500
https://www.nasdaq.com/symbol/alt/after-hours
ALT
Lot of active trading after-hours -- negative. Maybe 20,000 shares and have taken it down to .739. No news on the company website.
ALT
Sold at opening @ $3.14 which was approximate target price. Look to re-enter on any dip as the company fundamentals and technicals remain about the same.
TNXP
I'm far from being expert and wouldn't want anyone to trade on my advice. I merely post charts, observations and information regarding stocks in which I'm currently invested. Hence, generally I make a post when I buy in and one when exiting.
ALT certainly has great potential in the long run with a catalyst within months (early 3rd quarter) and according to the CEO, funds up to 2019 suggesting but not guaranteeing no near term raise. The company was local for me until it moved to Gaithersburg MD which is a biotech and high tech hub and a good place for them to be. From what I read in local papers it is a very legitimate and well respected company, something not always found among such developing companies.
I re-entered for short swing (not looking currently to be long in ALT mainly due to the volatility of the overall market) because I had noted a recent pattern of the stock being driven down early and then bouncing back to opening price and higher and then dropping back. Was looking to catch the top of the bounce to sell. However, for whatever reason on the last 2 trading days there developed an unusually tiny spread with high volume but no volatility. I don't believe folks are entering these bids/asks out to the thousandth place; rather, the Market Makers are doing this for whatever reason. I suppose you realize that MMs bids and asks are not 1:1 to what traders offer. They can be higher or lower although the trader's actual bid or ask is the price recorded for the traders's shares. So if your bid is .82 the MM representing you could be paying .8237 per share to get you your wanted shares for which you will pay .82. You may already know this, but some folks don't
Good luck with this trade.
ALT
Rarely see such tight range on a stock in this price range and certainly not on this one which usually has a large spread. As you note developed yesterday.
All I know is the MMs get a percentage of every trade and they are the only winners. Feel like wasting some money trying to raise the bid and see what happens. I'm sure they will sell and then resume the trade pattern.
We'll see.
ALT
Sold @ $14.96. Made a sandwich. Hearing Trump is about to go crazy later today -- too risky.
NUAN
Back in @ .85. Not sure why other than to get a chance to complain about MMs making a fortune on trading this company. Yesterday was one of its recent highest volume days and a good portion was MMs trading between .8351 and .8352. This went on for several hours. What dollar stock trades like that unless the MMs collude to get their cut off trading volume? Many brokers won't even place such n order.
ALT
Out for now @ $5.67 near the EOD. Chart broke @ 3:15. Good gain for the day. Geo-political and political issues scare me from holding overnight especially after gains.
NVTA
Head to Head Review: Tonix Pharmaceuticals (TNXP) versus The Competition
Posted by Joseph McCarthy on Apr 11th, 2018 // No Comments
Tonix Pharmaceuticals (NASDAQ: TNXP) is one of 484 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Tonix Pharmaceuticals to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
Profitability
This table compares Tonix Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals N/A -74.46% -69.58%
Tonix Pharmaceuticals Competitors -3,102.68% -152.82% -26.71%
Risk & Volatility
Tonix Pharmaceuticals has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals’ rivals have a beta of 1.08, indicating that their average share price is 8% more volatile than the S&P 500.
Earnings and Valuation
This table compares Tonix Pharmaceuticals and its rivals revenue, earnings per share and valuation.
Gross Revenue Net Income Price/Earnings Ratio
Tonix Pharmaceuticals N/A -$21.12 million -1.05
Tonix Pharmaceuticals Competitors $2.03 billion $132.97 million -3.45
Tonix Pharmaceuticals’ rivals have higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
15.4% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Tonix Pharmaceuticals and its rivals, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals 0 0 4 0 3.00
Tonix Pharmaceuticals Competitors 2761 8456 21244 566 2.59
Tonix Pharmaceuticals presently has a consensus target price of $8.33, indicating a potential upside of 174.12%. As a group, “Pharmaceutical preparations” companies have a potential upside of 44.66%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Tonix Pharmaceuticals is more favorable than its rivals.
Summary
Tonix Pharmaceuticals beats its rivals on 7 of the 13 factors compared.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
__________________________________________________
https://theenterpriseleader.com/2018/04/11/head-to-head-review-tonix-pharmaceuticals-tnxp-versus-the-competition.html
Interesting, but can't verify the info.
TNXP
Very nice, was hoping for +10%, but keeps getting stronger as the day goes on. (LABU up ~3%).
NVTA
InVitae +3.7% as Baker Bros. reports 12.6% stake
Apr. 10, 2018 6:36 PM ET|By: Jason Aycock, SA News Editor
InVitae (NYSE:NVTA) is up 3.7% after hours alongside a new 13G filing from Baker Bros. Advisors.
The firm reports a 12.6% passive stake in InVitae. That's based on 53.71M shares of the company outstanding as of March 19, plus 11.11M shares outstanding as part of a public offering (and 1.67M shares in a greenshoe option).
Baker Bros. had previously filed on 13D, but notes it now holds shares "in the ordinary course of business without the purpose of or with the effect of changing or influencing the control of the Issuer and do not hold such securities in connection with or as a participant in any transaction having that purpose or effect."
__________________________________________________
https://seekingalpha.com/news/3344834-invitae-plus-3_7-percent-baker-bros-reports-12_6-percent-stake
NVTA
Up after hours (but can't trade with E-trade account). Baker Bros pick up more shares?
NVTA
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing
Tue April 10, 2018 7:30 AM|PR Newswire|About: NVTA
CHARLOTTE, N.C., April 10, 2018 /PRNewswire/ --
Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present findings showing proactive genetic health screening reveals medically significant findings for a substantial portion of patients, and looking for secondary findings during genetic testing provides a substantial yield of actionable risk factors for disease. The studies are among the company's data being presented this week at the American College of Medical Genetics (ACMG) annual meeting in Charlotte, NC.
https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg
Healthy individuals are increasingly seeking genetic testing to identify their personal risks for inherited conditions such as cancer and cardiovascular disease. An analysis of 1,300 patients tested with a diagnostic-grade genetic screening panel designed for healthy adults found clinically actionable results in 16 percent of patients, predominantly in genes associated with an elevated risk for cancer or cardiovascular disease.
"Healthy adults are increasingly interested in using genetic information to understand their risk of disease and these data show that interest is warranted. But it is essential that consumers receive medically sound testing to assess their risk of diseases like cancer where monitoring and early intervention can be helpful," said Robert Nussbaum, M.D., chief medical officer of Invitae (NVTA). "Talking about genetic screening with a physician or genetic counselor and then using the highest quality testing can help ensure people receive accurate results and, just as importantly, sound medical advice on how to respond to those findings."
Invitae's proactive genetic tests are currently being provided at a number of institutions enabling clinicians to use this type of genetic screening with patients in a variety of clinical settings, including primary care.
In another platform presentation at the meeting, researchers from the company are reporting on an analysis of the frequency of actionable variants in hereditary cancer syndrome genes found in more than 3,000 patients referred for testing for hereditary cardiovascular disorders. Under an IRB-approved protocol that allowed review of de-identified test data, the researchers analyzed genetic testing results for a number of well-known genes associated with increased cancer risk in patients with no known indication for hereditary cancer gene testing. The researchers found that six percent of patients had pathogenic variants in clinically actionable hereditary cancer genes.
"Current ACMG guidelines on secondary findings support providing such information regardless of the original indication for testing," said Dr. Nussbaum, one of the authors of the study. "Our study indicates that one in 16 individuals could receive actionable information from hereditary cancer gene testing even in the absence of personal or family history that would suggest the need for a diagnostic evaluation of cancer risk. The results suggest the importance of screening for medically actionable gene mutations regardless of original indication."
The company's research presentations includes one platform presentation, one plenary presentation, and participation in fourteen posters at the meeting:
Wednesday, April 11
Platform presentation, 5:15 p.m. Eastern:
Secondary Findings in Hereditary Cancer Genes from Multigene Panel Data: A New Frontier Unanticipated by the ACMG
Presenter: Ed Esplin, MD, PhD, FACMG, FACP
Presentation #40
Thursday, April 12
Plenary presentation, 9:30 a.m. Eastern:
An Interlaboratory Study of Complex Variant Detection in Clinical Testing
Presenter: Stephen Lincoln
Poster presentations, 10:00 a.m. – 11:30 a.m. Eastern:
Poster #81: Diagnostic yield analysis of Invitae's metabolic analyte panels
Presenter: Michelle Fox, MS, LCGC
Poster #333: The Paperwork Matters! Phenotypic Information Significantly Impacts Variant Interpretation in Hereditary Cancer Testing
Presenter: Carolina Pardo, PhD
Poster #355: Detection of NF1 variants by NGS Panels with SNV and CNV Identification Exceeds Published Estimates and Improves Clinical Utility
Presenter: Karen Ouyang, PhD, FACMG
Poster #379: Behind the Seizure™: A No-Cost, 125-Gene Epilepsy Panel for Pediatric Seizure Onset Between 2-4 Years
Presenter: Nicole Miller, PhD
Poster #723: Current challenges in the classification of large genetic events affecting TTN
Presenter: Matteo Vatta, PhD, FACMG
Friday, April 13
Poster presentations, 10:30 a.m. – Noon Eastern:
Poster #142: The Clinical Impact of Mutations beyond BRCA1/BRCA2 in Breast Cancer Patients
Presenter: Judith Westman, MD
Poster #166 - Blue Ribbon: Down Syndrome Resources from the National Institutes of Health: Research Projects Supported by the DS-Connect® Registry
Presenter: Melissa Parisi, MD, PhD
Poster #218: ClinGen's GenomeConnect Registry Enables Patient-Centric Data Sharing
Presenter: Juliann Savatt, MS, LGC
Poster #326: Reducing VUS Rates Among Ethnic Groups: Sequencing Smarter, Not Harder
Presenter: Shan Yang, PhD
Poster #458: Quantitative Determination of SMN2 Copy Number using Next Generation Sequencing and Correlation to Disease Severity
Presenter: Sarah Klemm, MS
Poster #572: Are we ready for Telegenetics? Surveying the current landscape among ACMG members
Presenter: Shweta Dhar, MD, MS
Poster #622: Misattributed Paternity as an Unanticipated Finding During Exome/Genome Sequencing: Current Clinical Laboratory Practices and an Opportunity for Professional Recommendation Development
Presenter: Celeste Eno, PhD
Poster #628: Improved Diagnostic Confirmation of Newborn Screening Conditions by Next-Generation Sequencing: A Collaboration Between Laboratory and Clinician
Presenter: Michelle Fox, MS, LCGC
Poster #666: Multigene Panel Screening for Hereditary Disease Risk in Healthy Individuals
Presenter: Eden Haverfield, PhD, FACMG
About Invitae Corporation
Invitae Corporation (NYSE: NVTA) is a genetic information company. Invitae's mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the utility of proactive genetic screening; the increase in healthy individuals seeking genetic testing to identify personal risks for inherited conditions; and the importance of assessing secondary findings in genetic testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's ability to continue to generate substantial demand for its tests: the company's ability to compete; the company's history of losses; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2017. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Source: Invitae Corporation
Contact:
Laura D'Angelo
pr@invitae.com
314-920-0617
https://c212.net/c/img/favicon.png?sn=SF61319&sd=2018-04-10 View original content with multimedia:http://www.prnewswire.com/news-releases/invitae-research-highlights-utility-of-proactive-genetic-screening-importance-of-assessing-secondary-findings-in-genetic-testing-300626957.html
SOURCE Invitae Corporation
__________________________________________
NVTA
Hard to say. Shouldn't believe company PR's but they hold out hope:
_____________________________________________________
At the Cross-disciplinary Breakthrough Therapy meeting, the FDA indicated that a single-study New Drug Application (NDA) approval is possible, based on the interim or end-of-study analysis of the HONOR study, if the results are statistically persuasive. The company is ready to file an NDA for Tonmya for the treatment of PTSD in 2019 in the event of a persuasive outcome of the HONOR study.
____________________________________________________
https://finance.yahoo.com/news/tonix-pharmaceuticals-achieves-50-percent-110000834.html
Hard to say if this was 1 on 1 meeting or one for a number of recipients (Cross-disciplinary Breakthrough Therapy meeting) which were receiving guidelines.
Like the pipeline for such a small company and appreciate the target population.
Would like to see the pps up more given they presented today and the sector is up big, but with tiny float things don't move lockstep.
Great comments.
TNXP
April Investor Presentation:
https://content.equisolve.net/tonixpharma/media/8eda28b657c2bd5e9adc28c8b7905723.pdf
TNXP